I have long had the idea that God created psoriasis and warts to teach dermatologists the merits of humility.
(Vincent Joseph Derbes, 1981)
Facebook: VN Dermatology
Monday, December 19, 2011
Single-blind, randomized controlled trial evaluating the treatment of facial seborrheic dermatitis with hydrocortisone 1% ointment compared with tacrolimus 0.1% ointment in adults
Papp KA, Papp A, Dahmer B, Clark CS; Journal of the American Academy of Dermatology (Nov 2011)
BACKGROUND: Tacrolimus is a topical calcineurin inhibitor with
immunomodulatory, anti-inflammatory, and fungicidal properties that may
be beneficial in the treatment of facial seborrheic dermatitis.
OBJECTIVES: We sought to compare the efficacy and safety of tacrolimus
with standard corticosteroid treatment in adults with facial seborrheic
dermatitis in a phase II, single-blind, randomized controlled trial.
METHODS: Adult patients were enrolled in a 12-week study. Subjects were
randomized to tacrolimus 0.1% ointment (n = 16) or hydrocortisone 1%
ointment (n = 14) applied twice daily to symptomatic regions of the
face. The primary efficacy measure was the severity of facial seborrhea
at the end of treatment (day 84) as measured by the Seborrhea Area and
Severity Index-Face. Secondary efficacy measures included physician and
patient assessment of seborrhea, the frequency of medication
application, and adverse events. RESULTS: The severity of facial
seborrhea was similarly improved in both treatment groups (P = .86).
Tacrolimus 0.1% ointment was used on significantly fewer days than 1%
hydrocortisone ointment (mean missed doses per patient at first visit:
15.6 vs 7.6, P<.05; at last visit: 13.5 vs 7.7, P = .08). The
majority of doses were missed because of lack of symptoms. The adverse
event profile for both agents was similar; however, there was a
numerically higher incidence of adverse events in the hydrocortisone
group. LIMITATIONS: This was a small, open-label study. CONCLUSION:
Tacrolimus 0.1% ointment required significantly fewer applications
compared with hydrocortisone 1% ointment to achieve a comparable
clinical response in adults with facial seborrheic dermatitis.
Tacrolimus was generally well tolerated.
*.General Surgeon (Hue,VN); *. ENT (Hue,VN); *. Leprosy Surgeon (I.L.A.D); *.Leprologist (C.E.S de Léprologie, Dakar, Senegal); *.Level II Dermatologist (HCMC);
*.Speaker at The Combined Congress of 27th Asean Orthopedic Association-6th Vietnamese Orthopedic Association-12th Spine society of HCM city (HCMC-December, 2007); *.International Hospital Federation 1996 Associate Fellow (Hongkong-London);
*.Fellowship in Saint- Louis Hospital at Department of Plastic Surgery and Department of Dermatology (Paris, 2008).
*.Fellow of Ho Chi Minh Society for Laser in Medicine and Surgery ;
*.Fellow of Vietnamese Society of Dermatology and Venereology;
*.International Fellow of American Academy of Dermatology